Femasys (FEMY) Operating Income (2020 - 2026)
Femasys' (FEMY) quarterly Operating Income came in at -$5.1 million in Q2 2026, down 31.53% on a YoY basis from -$7.4 million in Q2 2025, and down 31.53% quarter-over-quarter from -$3.9 million in Q2 2025.
Analysis
Femasys (FEMY) Operating Income (2020 - 2026) Analysis & Trends
Femasys (FEMY) has reported Operating Income for 7 consecutive years, with -$5.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Income fell 31.53% year-over-year to -$5.1 million; the trailing twelve-month figure through Jun 2026 stood at -$19.1 million (changed 0.27% YoY), and the FY2025 full-year result was -$17.6 million, up 1.11% from the prior year.
- Operating Income fell to -$5.1 million in Q2 2026 per FEMY's latest filing, from -$3.9 million in the prior quarter.
- Across five years, Operating Income topped out at -$2.7 million in Q2 2022 and bottomed at -$5.5 million in Q1 2025.
- Historically, Operating Income has averaged -$3.9 million across 5 years, with a median of -$3.9 million in 2025.
- The sharpest annual moves came in 2022 and 2025: Operating Income slumped 57.83% in 2022, then gained 14.07% in 2025.
- Over 5 years, Operating Income stood at -$3.0 million in 2022, then slumped by 48.3% to -$4.4 million in 2023, then retreated by 6.14% to -$4.7 million in 2024, then gained by 18.44% to -$3.9 million in 2025, then plunged by 31.53% to -$5.1 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$5.1 million, -$3.9 million, and -$5.5 million for Q2 2026, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 1.69 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 971.90 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 1.76 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 1.66 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 1.18 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 513.20 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 11.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 318.30 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 285.80 Mn |
| 10 | Femasys | 9.37 Mn | 7.92 Mn | 189,391.00 | -5.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.07 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Mar 31, 2025 | -5.46 Mn |
| Dec 31, 2024 | -4.72 Mn |
| Sep 30, 2024 | -5.12 Mn |
| Jun 30, 2024 | -4.48 Mn |
| Mar 31, 2024 | -3.46 Mn |
| Dec 31, 2023 | -4.45 Mn |
| Sep 30, 2023 | -4.08 Mn |
| Jun 30, 2023 | -2.94 Mn |
| Mar 31, 2023 | -3.04 Mn |
| Dec 31, 2022 | -3.00 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Jun 30, 2022 | -2.66 Mn |
| Mar 31, 2022 | -2.88 Mn |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | -2.25 Mn |
| Jun 30, 2021 | -1.90 Mn |
| Mar 31, 2021 | -1.83 Mn |
| Dec 31, 2020 | -1.66 Mn |